Product/Service

Infectious Disease

Source: QuintilesIMS
We are facing an alarming increase of drug resistant microorganisms, global spread of infectious disease and the threat of bioterrorism and the development of antimicrobial agents is complex and expensive.

We are facing an alarming increase of drug resistant microorganisms, global spread of infectious disease and the threat of bioterrorism and the development of antimicrobial agents is complex and expensive. The field is constantly changing with the re-emergence of old foes such as polio, cholera and tuberculosis — and the appearance of new threats, including SARS, H1N1, and HIV.

Given these realities, there is a desperate need for new and improved vaccines to prevent disease, and new antimicrobial agents with improved efficacy and safety delivered in a timely and cost-effective manner.

Through our extensive experience in infectious diseases trials and our leadership position in this therapeutic area, we have been able to consistently deliver results that meet or exceed the requirements and expectations of our sponsors with:

  • Rapid enrollment during peak illness seasons
  • Large patient recruitment in both developed and developing regions
  • Monitoring complex studies of long duration
  • Ensuring global regulatory requirements are met

Rely on — and be confident in — our ability to get the job done the way you want it. For example, we've monitored over 750 trials, enrolling more than 628,000 patients at 25,000 sites worldwide since 2000.